Omega 3 Dry Eye Disease Meta-analysis: What the Evidence Says

Quick Answer

Omega 3 Dry Eye Disease Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• In particular, the estimated prevalence of DED increased to 61.0% globally and 56.7% in Asia during the COVID-19 pandemic, markedly higher than the levels prior to the pandemic, possibly due to the proliferation of remote work and online education. [Liu Jiaxiang (2026); evidence level 4]
• Additional contributing factors include incomplete blinking-often associated with prolonged screen use-and direct damage to the corneal epithelial glycocalyx. [Liu Jiaxiang (2026); evidence level 4]
• Although this form is less common, it is associated with a poorer prognosis and accounts for nearly 80% of severe vision loss caused by AMD. [Muacevic Alexander (2026); evidence level 4]
• The study concluded that consumption of the AREDS formula reduced the risk of progression by 25% over five years in patients with intermediate AMD or advanced disease in one eye. [Muacevic Alexander (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For omega 3 dry eye disease meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Liu Jiaxiang (2026). Advances in Pharmacotherapy and Physiotherapy for Dry Eye Disease: Molecular Mechanisms and Future Directions—A Narrative Literature Review. DOI: 10.3390/ijms27094024. PMCID: PMC13163669. PMID: 42123603. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13163669/
• Muacevic Alexander (2026). The Effect of Nutrition on Dry Age-Related Macular Degeneration: A Systematic Narrative Review of Evidence and Clinical Implications. DOI: 10.7759/cureus.106966. PMCID: PMC13170399. PMID: 42137658. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13170399/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.